Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC/CBD versus placebo for symptom control in advanced cancer receiving palliative care
ACTRN12619000037101Phase 2Completed
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer comparing THC/CBD with Placebo (2 arms). Primary endpoint: Change from baseline in total ESAS TSDS. Started Sep 2019; status: completed.
02
Drugs
dronabinolcannabidiol
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12619000037101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000037101.